CompuGen, an early stage drug and diagnostic discovery Company announced today a “Discovery on Demand” therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted molecules will be synthesized and delivered to Pfizer for further development. Pfizer will have the right to exercise options for a worldwide exclusive milestone and royalty agreement. CompuGen stock was up 64% today to $4.45.CGEN also has agreements with several other drug and diagnostic companies.
Other small cap “biodiscovery plays” ( genomics, diagnostics and biomarkers) that moved today were :
Celera (CRA) up 3.9% at $6.70
Helicos (HLCS) up 4.8% at $1.08
Myriad Genetics (MYGN) up 3.5% at $25.83
Sequenom (SQNM) up 5% to $4.35